Main content

Potentiating Cancer Immunotherapy with Antigen-Agnostic Therapies

Show simple item record

dc.contributor.advisor Bridle, Byram
dc.contributor.advisor Wootton, Sarah
dc.contributor.author van Vloten, Jacob
dc.date.accessioned 2020-04-14T20:29:24Z
dc.date.copyright 2020-02-21
dc.date.created 2020-02-21
dc.date.issued 2020-04-14
dc.identifier.uri http://hdl.handle.net/10214/17856
dc.description.abstract Cancer remains a lead health concern for human and veterinary patients. We are entering a new era of cancer therapy, driven by extensive evidence that the patient’s immune system holds the key to beating cancer. Immunotherapy encompasses any therapeutic modality with the explicit goal of activating the host immune response against malignancy. Immunotherapy has already produced therapies that are being used clinically. Oncolytic viruses (OV) are immunotherapeutics that use a diverse set of cancer-targeting viruses to engage host anticancer immunity. OVs are multi-mechanistic tools, each with unique biological characteristics. A key component of OVs is the ability to generate inflammation in the tumor microenvironment, recruiting effector cells and driving tumor-specific adaptive immune responses. In this thesis, two methods for evaluating the adaptive immune response to cancer are developed. These methods enable the quantification of tumor-specific T-lymphocyte and tumor-directed antibody responses without the need to identify a specific target antigen. Next, we demonstrate that fever can dramatically impact the oncolytic efficacy of two intensely studied OVs, vesicular stomatitis virus and Maraba virus, both from the Rhabdoviridae family. We developed a heat-adapted Maraba virus functional at fever-grade temperatures, and make recommendations for preclinical and clinical evaluation and implementation of OVs with regards to temperature. The final two research chapters evaluate the poxvirusParapoxvirus ovis (OrfV) as an oncolytic virus in two challenging models of late-stage ovarian cancer and osteosarcoma lung metastases. In both models, OrfV was a dramatic immune-stimulating OV platform that could circumvent the host antiviral interferon response and kill cancer cells by immunogenic cell death. OrfV massively recruited tumoricidal natural killer cells that directly kill tumor cells, release tumor antigen and guide the development of adaptive antitumor immune responses. The work in this thesis provides tools for researchers to detect anticancer immune responses in hosts, uncovers fever as a previously under-appreciated Achilles heel of some OVs and presents OrfV as a multi-functional immunogenic OVs deserving of further investigation and clinical translation. en_US
dc.language.iso en en_US
dc.rights Attribution 4.0 International *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ *
dc.subject Immunology en_US
dc.subject Virology en_US
dc.subject Vaccination en_US
dc.subject Oncolytic en_US
dc.subject Immunogenic cell death en_US
dc.subject T cell response en_US
dc.title Potentiating Cancer Immunotherapy with Antigen-Agnostic Therapies en_US
dc.type Thesis en_US
dc.degree.programme Pathobiology en_US
dc.degree.name Doctor of Philosophy en_US
dc.degree.department Department of Pathobiology en_US
dc.description.embargo 2021-02-21
dc.rights.license All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated.


Files in this item

Files Size Format View
vanVloten_Jacob_202004_PhD.pdfuntranslated 19.88Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International